: Inside the NASH drug boom: New drugs for a ‘silent’ liver disease that affects millions near FDA approval

Read Time:5 Second

Madrigal Pharmaceuticals’ resmetirom is a leading treatment candidate for the advanced form of fatty liver disease.

About Post Author

Happy

0 %

Sad

0 %

Excited

0 %

Sleepy

0 %

Angry

0 %

Surprise

0 %

Strategists at Citi are concerned about the possibility of a repeat, though they aren’t recommending investors trim their positions.

Enphase’s revenue in Europe dropped about 15% quarter-on-quarter as demand softened.

Shares of Starbucks fell on Tuesday after the coffee chain offered fresh signs of its struggle to bring back consumers,...

“We can envision a post-election scenario where uncertainty rises and trust in U.S. institutions declines,” Macquarie strategist Thierry Wizman said.

Verizon’s third quarter didn’t include too many days of iPhone 16 sales, but the company’s low upgrade rate is still...

People age 65 need to understand this key risk before signing up.